Stromal Vascular Fraction (SVF) Cell Injection Therapy is an investigational treatment to advance the future of knee osteoarthritis treatment.
Be the first to offer it in your market.
Here are the results one year after a single upfront injection. Read the study results here.
To date, no other long-term injectable treatment for knee osteoarthritis has successfully completed a pivotal Phase 3 clinical trial demonstrating statistical significance versus a sham control.
For many patients, the journey can feel like choosing between temporary symptom relief and a major surgical procedure, highlighting the need for continued research into new treatment approaches.
SVF Cell Injection Therapy remains investigational and has not been approved by the FDA for commercial use.
Following completion of a Phase 3 clinical study, the company continues to pursue FDA Premarket Approval (PMA) for its investigational SVF Cell Injection Therapy. Using cells derived from a patient’s own adipose tissue, researchers have studied whether this minimally invasive outpatient approach may support the body’s natural healing processes and improve symptoms of knee osteoarthritis.
SVF Cell Injection Therapy remains investigational and has not been approved by the FDA for commercial use.
SVF (Stromal Vascular Fraction) cells are isolated from the patient’s own adipose tissue.
These aren’t modified, cultured, or sourced from another person. They are the exact cells the patient’s body already deploys in response to tissue injury, including fibroblasts, mesenchymal stromal progenitors, pericytes, and endothelial cells. They are filtered, separated, concentrated, and then delivered at a guaranteed therapeutic dose of over 25 million cells.
SVF Cell Injection Therapy remains investigational and has not been approved by the FDA for commercial use.
The GID BIO Phase 3 pivotal clinical trial is the first and only injectable long-term therapy for knee osteoarthritis to achieve both safety and efficacy at a 12-month endpoint.
SVF Cell Injection Therapy remains investigational and has not been approved by the FDA for commercial use.
The results revealed:
GID BIO’s SFV Cell Injection Therapy is a point-of-care procedure. It’s designed to fit into a physician’s existing workflow with minimal disruption and maximum return.
SVF Cell Injection Therapy remains investigational and has not been approved by the FDA for commercial use.
“I’m a testimonials from trial participants who speak to the transformative effect SVF therapy has had on their life.”
David Elson, USA
“I’m a testimonials from trial participants who speak to the transformative effect SVF therapy has had on their life.”
David Elson, USA
“I’m a testimonials from trial participants who speak to the transformative effect SVF therapy has had on their life.”
David Elson, USA
GID BIO’s procedure is a closed-loop, 4-point-of-care system.
From harvest to injection, the patient never leaves the outpatient setting.
A small amount (30cc) of adipose (fat) tissue is removed from the patient’s abdomen or flank under local anesthesia via a single, small-cannula entry point. The patient is awake and comfortable throughout.
Harvested tissue goes directly into the SVF-2 sterile disposable canister, never leaving the closed system. The device filters, washes, and enzymatically dissociates the tissue, removing blood, fat cells, and extracellular matrix.
Cell count is measured at point of care before the dose is prepared. The physician confirms the dose meets the therapeutic threshold — over 25 million cells — before proceeding.
Using imaging guidance, the physician injects the SVF preparation directly into the intra-articular joint space. The patient is discharged the same day. No recovery room. No anesthesia reversal. No overnight observation.
SVF Cell Injection Therapy remains investigational and has not been approved by the FDA for commercial use.
SVF Cell Injection Therapy remains investigational and has not been approved by the FDA for commercial use.
The procedure is anticipated to have compelling CMS reimbursable with a simple, easy process and same-day patient recovery and discharge.
GID BIO’s SVF Cell Injection Therapy program will launch with a select group of committed physician partners. Request a meeting to learn more and be notified when applications open, and position your practice as a pioneer in knee osteoarthritis care.
SVF Cell Injection Therapy remains investigational and has not been approved by the FDA for commercial use.
